We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,024.00
Bid: 12,024.00
Ask: 12,028.00
Change: 36.00 (0.30%)
Spread: 4.00 (0.033%)
Open: 12,254.00
High: 12,256.00
Low: 12,018.00
Prev. Close: 11,988.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Weak Pound Boosts FTSE 100; Countrywide Surges 18%

Mon, 07th Dec 2020 08:58

(Alliance News) - Stock prices in London opened mixed on Monday with the internationally exposed FTSE 100 benefiting from weakness in the pound.

M&A news was providing investors with added interest Monday morning, with Countrywide and Elementis, among others, receiving takeover offers.

UK Prime Minister Boris Johnson and European Commission President Ursula von der Leyen will assess whether a post-Brexit trade deal can be salvaged following a weekend of tense negotiations.

The two leaders will speak on Monday evening - their second call in a little over 48 hours - after their top negotiators spent Sunday locked in detailed talks.

David Frost and his EU counterpart Michel Barnier were ordered back to the negotiating table in a final push to see if they could break the stalemate.

However Irish premier Micheal Martin, who has been closely following the talks process, warned that they remained on a "knife-edge". Martin said there appeared to be a "very challenging issue" still to be resolved over the so-called "level playing field" rules on fair competition.

All eyes are on an EU summit on Thursday, with the prospect that any deal - or the failure to find one – will be put to the bloc's 27 leaders at that time. A source close to the talks said the situation was "very difficult" and that negotiations were in their "last useful days".

Without a deal, tariffs would be levied on the huge volumes of trade passing between the UK and the European continent, through the Channel tunnel and by ship, starting on January 1.

The FTSE 100 index was up 10.19 points, or 0.1%, at 6,560.42 early Monday. The mid-cap FTSE 250 index was down 97.12 points, or 0.5%, at 20,085.57. The AIM All-Share index was up 0.4% at 1,072.74.

The Cboe UK 100 index was up 0.1% at 653.35. The Cboe 250 was down 0.5% at 17402.54. The Cboe Small Companies down 0.1% at 11,712.00.

In mainland Europe, the CAC 40 in Paris was down 0.7% while the DAX 30 in Frankfurt was down 0.5% early Monday.

The pound was quoted at USD1.3297 early Monday, sharply lower from USD1.3470 at the London equities close Friday.

At the end of last week, sterling breached the USD1.35 mark, reaching its strongest level since May 2018 on hopes of a Brexit trade agreement. However, cable fell sharply on nervousness over whether a deal will be agreed.

"The Brexit-weakened pound is giving the FTSE a leg up in addition to optimism surrounding the roll out of Pfizer's Covid vaccine which starts this week," said City Index analyst Fiona Cincotta. "The softer tone surrounding the pound is beneficial to multinationals on the FTSE 100 which earn abroad. This accounts for over 70% of the index, boosting it higher."

In the FTSE 100, AstraZeneca was up 2.0% after Morgan Stanley raised the Anglo-Swedish drugmaker to Overweight from Equal Weight. Additionally, on Sunday, AstraZeneca reported ACE-LY-004 phase II trial results, showing efficacy and a steady safety profile for Calquence in mantle cell lymphoma.

At the other end of the large caps, HSBC was down 2.1% after Bank of America downgraded the China-focused lender to Underperform from Neutral.

Elsewhere in London, Countrywide was up 18% at 302.32 pence after the estate agent received an improved offer from peer Connells. Connells offered 325p per share in cash, saying it raised its offer by 30% following discussions with Countrywide's major shareholders.

In response, Countrywide said it will evaluate the merits of the Connells offer but urged shareholders to take no action in the meantime.

Elementis was down 2.1% at 124.10p after the speciality chemicals company said that it received a revised conditional proposal from Minerals Technologies late Friday for a possible cash offer for Elementis at 130 pence per share.

The board of Elementis rejected the offer, saying it was significantly short of a value that would merit engagement and access to the company's non-public information, despite the "continued opportunistic bidding tactics of Minerals Technologies".

The euro was priced at USD1.2111, down from USD1.2140. Against the Japanese yen, the dollar was trading at JPY104.19, flat from JPY104.20.

Brent oil was quoted at USD49.05 a barrel on Monday morning, flat from USD49.08 late Friday. Gold was trading at USD1,838.02 an ounce, up from USD1,832.24.

The Japanese Nikkei 225 index ended down 0.8%. In China, the Shanghai Composite closed down 0.8%, while the Hang Seng index in Hong Kong finished down 1.3%.

Investor sentiment in Asia was hurt by reports that the US is considering fresh sanctions on several Chinese officials over their roles in the disqualification of lawmakers in Hong Kong, as Donald Trump presses ahead with his fight against Beijing before leaving office.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.